PLUG-SHAPED IMPLANT FOR THE REPLACEMENT AND REGENERATION OF BIOLOGICAL TISSUE AND METHOD FOR PREPARING THE IMPLANT
20220241078 · 2022-08-04
Inventors
- Egidius Gerardus Maria HERMSEN (CZ Eindhoven, NL)
- Everardus Johannes Hubertus VAN BUUL (AR 's-Hertogenbosch, NL)
- Giles William MELSOM (NP Bennekom, NL)
- Petrus Mattheus Mattheus Egidius Adrianus FRANSEN (MB Rosmalen, NL)
Cpc classification
A61F2002/3092
HUMAN NECESSITIES
A61F2002/30759
HUMAN NECESSITIES
A61L27/18
HUMAN NECESSITIES
A61L27/18
HUMAN NECESSITIES
A61F2002/30766
HUMAN NECESSITIES
A61F2/30965
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
International classification
A61L27/18
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
Abstract
A non-biodegradable plug-shaped implant (1) for the replacement and regeneration of biological tissue is described. The implant comprises a base section (2) configured for anchoring in bone tissue, and a top section (4) configured for growing cartilage tissue onto and into. The top section comprises a thermoplastic elastomeric material, which is porous. The thermoplastic elastomeric material comprises a linear block copolymer comprising urethane and urea groups, and may be substantially free of an added peptide compound having cartilage regenerative properties. The base section material further comprises one of a biocompatible metal, ceramic, mineral, such as phosphate mineral, and polymer, optionally a hydrogel polymer, and combinations thereof, wherein the thermoplastic elastomeric material further comprises carbonate groups.
Claims
1. A non-biodegradable implant for the replacement and regeneration of biological tissue in the shape of a plug, comprising a base section configured for anchoring in bone tissue, and a top section configured for replacing cartilage tissue of an intermediate and deep zone of a cartilage layer, and for growing cartilage tissue onto and into, thus regenerating a superficial zone of the cartilage layer, wherein the top section comprises a porous thermoplastic elastomeric material, wherein the thermoplastic elastomeric material comprises a linear block copolymer comprising urethane and urea groups, and wherein the base section material comprises one of a biocompatible metal, ceramic, mineral, and polymer, optionally a hydrogel polymer, and combinations thereof, wherein the thermoplastic elastomeric material further comprises carbonate groups.
2. The implant according to claim 1, wherein the thermoplastic elastomeric material is substantially free of an added peptide compound having cartilage regenerative properties.
3. The implant according to claim 1, wherein the thermoplastic elastomeric material comprises a poly-urethane-bisurea-alkylenecarbonate.
4. The implant according to claim 1, wherein the thermoplastic elastomeric material is aliphatic.
5. The implant according to claim 1, wherein the porous elastomeric material has an elastic modulus at room temperature of less than 8 MPa.
6. The implant according to claim 1, wherein the base section comprises a core of non-porous base section material and a circumferential shell of porous base section material, wherein the shell has a thickness that is less than 10% of a largest diameter of the base section.
7. The implant according to claim 1, wherein the base section extends between a top surface and a bottom surface, and comprises a layer of porous base section material, wherein the layer is adjacent to the top surface and has a thickness that is less than 10% of a largest height of the base section, and wherein the pores of the base section material in the layer comprise the biocompatible elastomeric material.
8. The implant according to claim 1, wherein the base section material comprises a metal, selected from titanium, zirconium, chromium, aluminum, stainless steel, hafnium, tantalum or molybdenum, and their alloys, or any combination thereof.
9. The implant according to claim 1, wherein the base section material comprises a ceramic or mineral, selected from oxides, nitrides, carbides and borides, or any combination thereof.
10. The implant according to claim 1, wherein the base section material comprises a (hydrogel) polymer, selected from collagen, poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), polyacrylamide, polyurethane, polyethylene glycol (PEG), chitin, poly(hydroxyalkyl methacrylate), water-swellable N-vinyl lactams, starch graft copolymers, and derivatives and combinations thereof.
11. The implant according to claim 1, wherein the base section material comprises a non-hydrogel polymer.
12. The implant according to claim 11, comprising a substantially non-porous polyaryletherketone polymer with a porosity of less than 20%, relative to the total volume of the polyaryletherketone polymer.
13. The implant according to claim 11, wherein the base section comprises a non-porous polyaryletherketone polymer.
14. The implant according to claim 1, further comprising a contrast or radiopharmaceutical agent or body for medical imaging, preferably provided in the base section.
15. The implant according to claim 1, wherein the top surface of the base section comprises irregularities or undulations.
16. The implant according to claim 1, wherein the base section comprises a centrally located cavity that comprises the elastomeric material.
17. The implant according to claim 1, wherein the base section comprises an outer surface having irregularities or undulations.
18. The implant according to claim 1, wherein a height of the base section, and a height of the porous top section are selected such that a top surface of the implant comes to lie below a top surface of cartilage present on a osteochondral structure when implanted.
19. The implant according to claim 1, wherein a height of the base section, and a height of the porous top section are selected such that a bottom surface of the top section comes to lie about level with a bottom surface of cartilage present on a osteochondral structure when implanted.
20. The implant according to claim 1, comprising a top section with a slightly curved top surface, having a radius of curvature in a sagittal plane and/or in a medial-lateral plane ranging from 15 mm to 150 mm.
21. The implant according to claim 1, wherein the base section material comprises a reinforcing material selected from the group consisting of fibrous or particulate polymers and/or metals.
22. A method for the preparation of an implant, comprising: a) providing in a mold at room temperature a base section that comprises base section material comprising one of a biocompatible metal, ceramic, mineral, and polymer, optionally a hydrogel polymer, and combinations thereof; and granules of a thermoplastic elastomeric material on top of the base section, the thermoplastic material comprising a linear block copolymer comprising urethane and urea groups; b) closing the mold and heating the above assembly to a temperature of between 100° C. and 250° C. under a pressure of between 1 and 2 GPa, such that the thermoplastic elastomeric material melts and fuses with the base section; and c) cooling the assembly to room temperature to consolidate the thermoplastic elastomeric material and opening the mold; d) providing a top section of the thermoplastic elastomeric material with pores either before or after opening the mold.
23. The method according to claim 22, wherein the thermoplastic elastomeric material is substantially free of an added peptide compound having cartilage regenerative properties
24. The method according to claim 22, wherein after step b) the mold is opened and additional granules of the thermoplastic elastomeric material are added to the mold, and step b) is repeated.
25. Osteochondral structure comprising an implant in accordance with claim 1, wherein a top surface of the implant lies below a top surface of the cartilage layer on the osteochondral structure.
Description
BRIEF DESCRIPTION OF THE FIGURES
[0069] The invention will now be further elucidated by the following figures and examples, without however being limited thereto. In the figures:
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080] Referring to
[0081]
[0082]
[0083]
[0084] Please note that in
[0085] Referring to
[0086] Referring to
[0087] Referring to
[0088] Referring to
[0089] Again note that in
[0090] Referring to
[0091] Preparation of the Elastomeric Material of the Top Section
Example 1: Polycarbonate—aliphatic: Poly(hexylene carbonate urethane)-bis-urea biomaterial MVH313, See Table 1 Below
[0092] This one-pot two-step produced Biomaterial MVH313 was prepared by functionalization of 1.0 molar equivalent of poly(hexylene carbonate) diol (MW=2000) with 2.0 molar equivalents of 1,6-diisocyanatohexane (step 1), and subsequent chain extension using 1.0 molar equivalent of 1,6-diaminohexane (step 2).
[0093] In particular, the aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the top section 4 was manufactured as follows (with reference to
[0094] .sup.1H NMR spectroscopy was performed on the resulting polymer, using a Varian 200, a Varian 400 MHz, or a 400 MHz Bruker spectrometer at 298K. DSC was performed using a Q2000 machine (TA Instruments). Heating scan rates of 10° C./min and 40° C./min were used for the assessment of the melting temperature (Tm) and the glass transition temperature (Tg), respectively. The Tm was determined by the peak melting temperature and the Tg was determined from the inflection point.
[0095] All reagents, chemicals, materials, and solvents were obtained from commercial sources and were used without further purification. The used poly(hexylene carbonate) diol had an average molecular weight of approximately 2 kg/mol.
[0096] The non-porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial had an elastic modulus according to ASTM D638 of 3.6±0.03 MPa.
Example 2: Polyether—aromatic: Poly(tetrahydrofuran urethane)-bis-urea biomaterial MVH309B, See Table 1 Below
[0097] In a similar one-pot two-step experimental procedure as described in detail for Biomaterial MVH313, Biomaterial MVH309B was also produced. Particularly, Biomaterial MVH309B was prepared by functionalization of 1.0 molar equivalent of poly-tetrahydrofuran diol (MW=2000) with 1.33 molar equivalents of bis(4-isocyanatophenyl)methane (MDI) (step 1), and subsequent chain extension using 0.33 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH309B was isolated as a white, flexible, tough elastomeric polymer.
Example 3: Polyether—aliphatic: Poly(tetrahydrofuran urethane)-bis-urea biomaterial MVH312, See Table 1 Below
[0098] In a similar one-pot two-step experimental procedure as described in detail for Biomaterial MVH313, Biomaterial MVH312 was also produced. Particularly, Biomaterial MVH312 was prepared by functionalization of 1.0 molar equivalent of poly-tetrahydrofuran diol (MW=2000) with 2.0 molar equivalents of 1,6-diisocyanatohexane (step 1), and subsequent chain extension using 1.0 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH312 was isolated as a flexible, tough elastomeric polymer.
Example 4: Polycarbonate—aromatic: Poly(hexylene carbonate urethane)-bis-urea biomaterial MVH311, See Table 1 Below
[0099] In a similar one-pot two-step experimental procedure as described in detail for Biomaterial MVH313, Biomaterial MVH311 was also produced. Particularly, Biomaterial MVH311 was prepared by functionalization of 1.0 molar equivalent of poly(hexylene carbonate) diol (MW=2000) with 1.33 molar equivalents of bis(4-isocyanatophenyl)methane (MDI) (step 1), and subsequent chain extension using 0.33 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH311 was isolated as a flexible, tough elastomeric polymer.
Mechanical Properties of the Elastomeric Material of the Top Section without Pores
[0100] Stress Relaxation Testing was performed on the two aromatic and two aliphatic polymers of Examples 1-4, as well as on three equine cartilage specimens obtained from the Utrecht Medical Centre. A description of the specimens (e.g. polymer classes) and their dimensions are listed in Table 1. Using an Instron Electropulse E10000, each specimen was compressed at a strain rate of 0.005 s-1 up to a strain of 0.05 mm/mm which remained constant for 1800 s. All tests were done in triplicate. During the tests, load, displacement and time were recorded and afterwards, stress relaxation curves were obtained from the data. Stress relaxation is shown by determining the stress relaxation modulus G(t) at the onset of stress relaxation (G(0)) and 1800 s after the onset of stress relaxation (G(1800)) using the following equation: G(t)=σ(t)/ε.sub.0, where σ(t) is the compressive stress and ε.sub.0 is the set (constant) strain.
TABLE-US-00001 TABLE 1 Overview of the stress relaxation tests. All tests were done in triplicate. Test Code Description Dimensions 1 EC Equine cartilage ∅8.5 × 1.55 × 0.28 mm (average of three specimens) 2 MVH309B Polyether based 10.8 × 10.5 × 3.0 mm (l × w × h) aromatic polymer 3 MVH311 Polycarbonate based 12.0 × 11.1 × 2.9 mm (l × w × h) aromatic polymer 4 MVH312 Polyether based 12.4 × 11.3 × 3.0 mm (l × w × h) aliphatic polymer 5 MVH313 Polycarbonate based 13.5 × 13.5 × 3.0 min (l × w × h) aliphatic polymer
[0101] The results are shown in Table 2 below.
TABLE-US-00002 TABLE 2 Stress relaxation moduli of the materials at and after 1800 s after the onset 9 of stress relaxation. Stress relaxation modulus [MPa] Test Code G.sub.(0) G.sub.(1800) 1 EC 1.32 ± 0.58 0.03 ± 0.02 2 MVH309B 0.85 ± 0.04 0.65 ± 0.04 3 MVH311 12.29 ± 0.30 10.84 ± 0.39 4 MVH312 10.36 ± 0.61 7.42 ± 0.28 5 MVH313 3.60 ± 0.03 3.14 ± 0.05
[0102] Preparation of Biomaterial-Capped Pekk Bone Anchors
[0103] The implant 1 was manufactured by attaching the top section 4 to a PEKK base section 2 which serves as bone anchor. In a method according to an embodiment of the invention, PEKK bone anchors were capped with the poly-urethane-urea-hexylene carbonate biomaterial by pressing small granules of the aliphatic polycarbonate polymer on top of and into the PEKK anchors. For this purpose, a custom press setup was used. Various temperatures (100° C. to about 150° C.), compressive forces (2 kN to about 4 kN) and methods have been tested. The best results were obtained using a two-step procedure, employing a temperature of 150° C. and using a compressive force of 40 kN (4 tons, or 4000 kg; corresponding to a pressure of 1.4 GPa). Lower temperatures than 150° C. seemed to give less homogenously pressed poly-urethane-urea-hexylene carbonate biomaterial layers (sections 3 and 4), while higher temperatures are less desired as the urea groups in the poly-urethane-urea-hexylene carbonate biomaterial may then degrade to some extent. In the first step, ca. 50 mg of the polymer 12 was pressed onto and into the PEKK bone anchor for 15 minutes, while in the second step, ca. 2 mg of polymer 12 was added to the setup and the sample was pressed for another 15 minutes under the same conditions (150° C. and 40 kN). The samples were subsequently removed from the compression setup and were then allowed to cool. After the second pressing step, the surface of the poly-urethane-urea-hexylene carbonate biomaterial layer (sections 3 and 4) on top of the base section 2 seemed to be substantially flat. The biomaterial was almost transparent and colorless. The edges of the biomaterial showed some fringes or frays, and these were removed using a scalpel.
[0104] A central hole (241, 242) of the base section 2 was about 4.5 mm deep and about 2 mm in diameter. The hole was substantially filled with the poly-urethane-urea-hexylene carbonate biomaterial, and the attachment of the biomaterial to the PEKK base section 2 seemed quite strong and robust. Removing the biomaterial from the PEKK base section by force, or loosening the connection at the PEKK-biomaterial interfaces, proved practically impossible. All used equipment and accessories that were intended to come into contact with the PEKK base section 2 and/or with the elastomeric biomaterial were rinsed with ethanol or isopropanol and were thereafter dried. After pressing, and cutting the frays, the PEKK-biomaterial plug implant was rinsed with isopropanol and dried. The plugs may also be produced in a sterilized environment, if needed.
[0105] As assessed by measuring, the PEKK base section was 6 mm in diameter and 6 mm tall (a height of 6 mm). The central cavity in the base section was about 2 mm in diameter and about 4.5 mm deep. The elastomeric biomaterial (the aliphatic polycarbonate) positioned onto the PEKK base section was about 6 mm in diameter and about 1 mm high. Accordingly, the total PEKK-biomaterial plug implant was about 7 mm tall.
[0106] The top section 4 was provided with pores by drilling holes in it with an average diameter of 300 micron, to a final porosity of 50 vol. %. The porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the top section 4 had an elastic modulus according to ASTM D638 of 0.9±0.2 MPa.
[0107] The implant 1 may be implanted into an osteochondral defect 8 as shown in
[0108] As also shown in
[0109] Finally, the implant according to the embodiment shown in
[0110] Preparation of Biomaterial-Capped Metallic Bone Anchors
[0111] Another embodiment of the implant 1 was manufactured by attaching the top section 4 to a titanium base section 2 which serves as bone anchor. The titanium used was alloy Ti6A14V, which is readily commercially available. The titanium base section was provided with pores having an average pore size of about 300 microns. In a method according to an embodiment of the invention, titanium bone anchors were capped with a poly-urethane-urea-hexylene carbonate biomaterial by pressing small granules of the aliphatic polycarbonate polymer on top of and into the pores of the titanium anchors. For this purpose, the same custom press setup as used in the previous example was used. Optimum results were again obtained using a two-step procedure, employing a temperature of 150° C. and using a compressive force of 40 kN (4 tons, or 4000 kg; corresponding to a pressure of 1.4 GPa). In the first step, ca. 50 mg of the elastomeric polymer was pressed onto and into the titanium bone anchor for 15 minutes, while in the second step, ca. 2 mg of the elastomeric polymer was added to the setup and the sample was pressed for another 15 minutes under the same conditions (150° C. and 40 kN). The samples were subsequently removed from the compression setup and were then allowed to cool. After the second pressing step, the surface of the poly-urethane-urea-hexylene carbonate biomaterial layer (sections 3 and 4) on top of the base section 2 seemed to be substantially flat. The biomaterial was almost transparent and colorless. Some edges of the biomaterial showed fringes or frays, which were removed using a scalpel.
[0112] As with the PEKK base anchor, the titanium base anchor was also provided with a central hole (241, 242) with the same dimensions. The hole was substantially filled with the poly-urethane-urea-hexylene carbonate biomaterial, and the attachment of the biomaterial to the titanium base section 2 was satisfactory.
[0113] The titanium base section 2 had the same dimensions as the PEKK base section. Since the same mold was used, the elastomeric biomaterial (the aliphatic polycarbonate) positioned onto the titanium base section was about 6 mm in diameter and about 1 mm high. Accordingly, the total titanium-biomaterial plug implant was about 7 mm tall.
[0114] The top section 4 was provided with pores by drilling holes in it with an average diameter of 300 micron, to a final porosity of 50 vol. %. The porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the top section 4 had an elastic modulus according to ASTM D638 of 0.9±0.2 MPa.
[0115] The implant 1 may be implanted into an osteochondral defect 8 as shown in
[0116] Surrounding native cartilage 5 grows onto a top side 41 of the top section 4 and new cartilage 5a is generated on top of the implant 1, as shown in
[0117] As also shown in
[0118] It will be apparent that many variations and applications are possible for a skilled person in the field within the scope of the appended claims of the invention.